Mirabilis Medical has announced that Universitätsklinik Bonn (the University Clinics and Medical School of Bonn) in Germany is now offering patients focused ultrasound treatment for uterine fibroids using their device.
The Foundation’s Director of Clinical Relationships, Suzanne LeBlang, MD, recently traveled to the site to see a treatment.
“I was honored to be invited to witness this international collaboration between the Mirabilis team and the clinicians at the University of Bonn,” said LeBlang. “The treatment itself was fast, and I am encouraged that they can now offer this noninvasive, outpatient treatment to their patients.”
In her clinical career, Dr. LeBlang performed more than 400 uterine fibroid treatments with focused ultrasound. In her practice, the focused ultrasound treatments were guided by magnetic resonance (MR).
“The Mirabilis system uses ultrasound guidance, which is more convenient for gynecologists and radiologists who are already using ultrasound as a diagnostic tool,” she shared. “This could significantly improve patient access to this technology.”
Mirabilis earned CE mark in March 2017 to market its device in the European Union. The device is not yet approved for commercial use in the US.
Read the Mirabilis Press Release >